Views: 0 Author: Site Editor Publish Time: 2024-08-17 Origin: Site
Atopic dermatitis (AD), also known as atopic eczema, is a widespread chronic inflammatory skin disorder marked by persistent erythema, itchy rashes, and elevated serum IgE levels. It affects millions of people across the globe, causing intense physical discomfort and severely reducing patients’ quality of life. The complex pathogenesis of AD involves genetic predisposition, impaired skin barrier function, and dysregulated immune responses, making it difficult to develop targeted and effective treatments. Reliable preclinical models that can faithfully recapitulate human AD pathophysiology are indispensable for research and therapeutic innovation. In this article, we elaborate on the core roles of atopic dermatitis (AD) models, their classification, and their vital value in advancing AD research and new drug development.
Atopic dermatitis is a multifactorial disease driven by the interplay of genetic, environmental, and immune factors. Clinically, patients present with recurrent pruritus, eczematous skin lesions, and increased susceptibility to skin infections. At the histological and immunological levels, AD is defined by epidermal hyperplasia, abnormal accumulation of mast cells, and a dominant Th2-biased immune response. These pathological and immunological characteristics are the key basis for constructing and evaluating preclinical AD models. A deep understanding of AD’s underlying mechanisms is essential for designing effective therapeutic strategies and validating novel drug candidates.
AD models are foundational tools for preclinical research in autoimmune and allergic skin diseases. They provide a controlled, repeatable experimental system to explore disease mechanisms, screen potential drugs, and bridge the gap between laboratory findings and clinical applications. These models are constructed through diverse methods including chemical induction, genetic modification, and environmental stimulation, each with unique applicability for different research objectives. By simulating the pathological and immunological features of human AD, these models enable researchers to conduct systematic and in-depth studies without ethical risks associated with human trials.
A variety of AD models have been developed to meet different research needs, each mimicking distinct aspects of human AD. The mainstream AD animal models include:
DNCB-induced AD model: Uses 2,4-dinitrochlorobenzene (DNCB) to trigger AD-like skin lesions; repeated hapten stimulation damages the skin barrier and induces a Th2-biased immune response, widely used in allergic contact dermatitis and AD progression research.
OXA-induced AD model: Employs oxazolone (OXA) to induce skin inflammation; it shifts the immune response from Th1 to Th2, simulating the transformation of contact dermatitis to AD.
MC903-induced AD model: Uses calcipotriol (MC903), a vitamin D analog, to upregulate TSLP expression and trigger type 2 skin inflammation, suitable for studying early AD pathogenesis and immune cell functions.
FITC-induced BALB/c AD model: Induces AD-like lesions in BALB/c mice with fluorescein isothiocyanate (FITC), mainly used to research dendritic cell migration, maturation, and hapten-specific T cell activation.
Non-human primate (NHP) AD model: Leverages non-human primates with high genetic similarity to humans; it is the most translational model for AD research and can also be induced by DNCB or OXA, making it ideal for late-stage preclinical validation.
Therapeutic efficacy testing: AD models provide a controlled platform to evaluate the effectiveness of new drugs, formulations, dosages, and administration routes, helping researchers screen out promising candidates.
Disease mechanism exploration: These models reveal the immune disorders, skin barrier defects, and genetic variations in AD, supporting the identification of novel therapeutic targets.
Biomarker identification: AD models assist in discovering biomarkers related to disease progression and treatment response, enabling precise diagnosis and personalized treatment.
Safety assessment: They support preliminary safety and toxicology evaluations of new drugs, identifying potential adverse reactions before clinical trials.
Despite their critical value, AD models have inherent limitations. No single model can fully replicate the full complexity and heterogeneity of human AD, and each model has its own advantages and constraints. Researchers must select the most appropriate model based on specific research purposes. Interspecies differences also pose challenges to translating preclinical findings from animal models to human clinical outcomes, requiring comprehensive verification and optimization.
HKeybio, the "Autoimmune Disease Model Expert", is a professional preclinical CRO focused on autoimmune and allergic diseases, providing full-process in vivo efficacy services. The company owns 500+ validated autoimmune and allergic disease animal models, including a full range of standardized AD models, as well as 50+ non-human primate autoimmune and allergic disease models represented by non-human primate AD models. With a core technical team boasting more than 20 years of experience and 300+ IND filing experiences for autoimmune diseases, HKeybio supports global pharmaceutical customers in completing high-quality AD preclinical research and regulatory submissions. For more details, please visit www.hkeybio.com or contact tech@hkeybio.com.
A: AD models provide a controllable preclinical platform to simulate human AD pathological features, study disease mechanisms, test drug efficacy, identify biomarkers and conduct drug safety evaluations.
A: Common chemically induced AD mouse models include DNCB-induced, OXA-induced, MC903-induced and FITC-induced BALB/c AD models.
A: Non-human primates have high genetic and immune system similarity to humans, which can better simulate human AD characteristics and provide more reliable data for late-stage preclinical drug verification.
A: AD models support drug efficacy screening, therapeutic target discovery, disease biomarker identification and preliminary drug safety/toxicology evaluation before clinical trials.
